Nucleus Commercial Holdings Limited
Annual Report and Financial Statements
For the year ended 31 March 2025
Company Registration No. 09646728 (England and Wales)
Nucleus Commercial Holdings Limited
Company Information
Directors
M Goldman
D Winward
G Titley
S Willmett
Company number
09646728
Registered office
4th Floor
120 Regent Street
London
W1B 5FE
Auditor
Moore Kingston Smith LLP
6th Floor
9 Appold Street
London
EC2A 2AP
Nucleus Commercial Holdings Limited
Contents
Page
Strategic report
1
Directors' report
2 - 3
Independent auditor's report
4 - 7
Profit and loss account
8
Statement of comprehensive income
9
Balance sheet
10
Statement of changes in equity
11
Statement of cash flows
12
Notes to the financial statements
13 - 19
Nucleus Commercial Holdings Limited
Strategic Report
For the year ended 31 March 2025
Page 1

The directors present the strategic report for the year ended 31 March 2025.

Fair review of the business

On behalf of the board

M Goldman
Director
30 September 2025
Nucleus Commercial Holdings Limited
Directors' Report
For the year ended 31 March 2025
Page 2

The directors present their report and financial statements for the year to 31 March 2020.

Principal activities

The principal activity of the company continued to be that of [XXXX]

Results and dividends

The results for the year are set out on page 8.

No ordinary dividends were paid. The directors do not recommend payment of a final dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

C Shah
(Resigned 27 September 2024)
M Goldman
D Winward
G Titley
S Willmett
Auditor
Energy and carbon report

[Amend this as an introductory paragraph or use as an explanation concerning lower user status] As the company has not consumed more than 40,000 kWh of energy in this reporting period, it qualifies as a low energy user under these regulations and is not required to report on its emissions, energy consumption or energy efficiency activities.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Nucleus Commercial Holdings Limited
Directors' Report (Continued)
For the year ended 31 March 2025
Page 3
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

On behalf of the board
M Goldman
Director
30 September 2025
Nucleus Commercial Holdings Limited
Independent Auditor's Report
To the Members of Nucleus Commercial Holdings Limited
Page 4
Opinion

We have audited the financial statements of Nucleus Commercial Holdings Limited (the 'company') for the year ended 31 March 2025 which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity, the Statement of Cash Flows and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report, other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

 

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Nucleus Commercial Holdings Limited
Independent Auditor's Report (Continued)
To the Members of Nucleus Commercial Holdings Limited
Page 5

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the Strategic Report or the Directors' Report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

 

Responsibilities of directors

As explained more fully in the Directors' Responsibilities Statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

 

In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Nucleus Commercial Holdings Limited
Independent Auditor's Report (Continued)
To the Members of Nucleus Commercial Holdings Limited
Page 6
Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

 

As part of an audit in accordance with ISAs (UK) we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

 

 

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

 

 

Nucleus Commercial Holdings Limited
Independent Auditor's Report (Continued)
To the Members of Nucleus Commercial Holdings Limited
Page 7

Explanation as to what extent the audit was considered capable of detecting irregularities, including fraud

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below.

The objectives of our audit in respect of fraud, are; to identify and assess the risks of material misstatement of the financial statements due to fraud; to obtain sufficient appropriate audit evidence regarding the assessed risks of material misstatement due to fraud, through designing and implementing appropriate responses to those assessed risks; and to respond appropriately to instances of fraud or suspected fraud identified during the audit. However, the primary responsibility for the prevention and detection of fraud rests with both management and those charged with governance of the company.

Our approach was as follows:

 

 

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

Ryan Day
Senior Statutory Auditor
for and on behalf of Moore Kingston Smith LLP
30 September 2025
Chartered Accountants
Statutory Auditor
6th Floor
9 Appold Street
London
EC2A 2AP
Nucleus Commercial Holdings Limited
Profit and Loss Account
For the year ended 31 March 2025
Page 8
2025
2024
Notes
£
£
Administrative expenses
(63,658)
(1,334,202)
Loss before taxation
(63,658)
(1,334,202)
Tax on loss
5
-
0
-
0
Loss for the financial year
(63,658)
(1,334,202)

The Profit and Loss Account has been prepared on the basis that all operations are continuing operations.

Nucleus Commercial Holdings Limited
Statement of Comprehensive Income
For the year ended 31 March 2025
Page 9
2025
2024
£
£
Loss for the year
(63,658)
(1,334,202)
Other comprehensive income
-
-
Total comprehensive income for the year
(63,658)
(1,334,202)
Nucleus Commercial Holdings Limited
Balance Sheet
As at 31 March 2025
Page 10
2025
2024
Notes
£
£
£
£
Fixed assets
Investments
6
4,632,101
4,633,401
Current assets
Debtors
8
2,624,873
1,501,601
Cash at bank and in hand
8,525
1,178,712
2,633,398
2,680,313
Creditors: amounts falling due within one year
9
(30,643)
(15,200)
Net current assets
2,602,755
2,665,113
Net assets
7,234,856
7,298,514
Capital and reserves
Called up share capital
10
100
100
Share premium account
1,199,911
1,199,911
Profit and loss reserves
6,034,845
6,098,503
Total equity
7,234,856
7,298,514
The financial statements were approved by the board of directors and authorised for issue on 30 September 2025 and are signed on its behalf by:
S Willmett
Director
Company Registration No. 09646728
Nucleus Commercial Holdings Limited
Statement of Changes in Equity
For the year ended 31 March 2025
Page 11
Share capital
Share premium account
Profit and loss reserves
Total
£
£
£
£
Balance at 1 April 2023
100
1,199,911
7,432,705
8,632,716
Year ended 31 March 2024:
Loss and total comprehensive income for the year
-
-
(1,334,202)
(1,334,202)
Balance at 31 March 2024
100
1,199,911
6,098,503
7,298,514
Year ended 31 March 2025:
Loss and total comprehensive income for the year
-
-
(63,658)
(63,658)
Balance at 31 March 2025
100
1,199,911
6,034,845
7,234,856
Nucleus Commercial Holdings Limited
Statement of Cash Flows
For the year ended 31 March 2025
Page 12
2025
2024
Notes
£
£
£
£
Cash flows from operating activities
Cash (absorbed by)/generated from operations
11
(1,171,187)
1,076,590
Investing activities
Proceeds from disposal of subsidiaries
1,300
1,301,922
Net cash generated from investing activities
1,300
1,301,922
Net (decrease)/increase in cash and cash equivalents
(1,169,887)
2,378,512
Cash and cash equivalents at beginning of year
1,178,712
100,111
Cash and cash equivalents at end of year
8,525
1,178,712
CASH FLOW OUT OF BALANCE BY:
300
1,299,911
Nucleus Commercial Holdings Limited
Notes to the Financial Statements
For the year ended 31 March 2025
Page 13
1
Accounting policies
Company information

Nucleus Commercial Holdings Limited is a private company limited by shares incorporated in England and Wales. The registered office is 4th Floor, 120 Regent Street, London, W1B 5FE.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

As at 31 March 2018, the group had net assets of £274,115 and incurred a loss of £926,089 for the year ended 31 March 2018. The group is funded through long term credit facilities with third party lenders and the amount owed at 31 March 2018 was £69,070,856. The Directors have confirmed that the profitable entities generating surplus cash will continue to support the loss making entities within the group, for at least one year from the date of approval of the accounts. Two substantial contracted fees were generated in the first quarter of the 2018/19 financial year which when taken into account in the forecasts for the year, will generate sufficient cash and profit for the group to continue as a going concern. The Directors have confirmed they are seeking further third party long term funding to refinance existing long term loans which will reduce the facility costs of these loans. It is anticipated that these loans will be refinanced shortly.  As such the accounts have been prepared on a going concern basis.  true

1.3
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

Nucleus Commercial Holdings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
1
Accounting policies
(Continued)
Page 14
1.4
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets

Financial assets are derecognised only when the contractual rights to the cash flows from the asset expire or are settled, or when the company transfers the financial asset and substantially all the risks and rewards of ownership to another entity, or if some significant risks and rewards of ownership are retained but control of the asset has transferred to another party that is able to sell the asset in its entirety to an unrelated third party.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Nucleus Commercial Holdings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
1
Accounting policies
(Continued)
Page 15
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

Other financial liabilities

Derivatives, including interest rate swaps and forward foreign exchange contracts, are not basic financial instruments. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently re-measured at their fair value. Changes in the fair value of derivatives are recognised in profit or loss in finance costs or finance income as appropriate, unless hedge accounting is applied and the hedge is a cash flow hedge.

 

Debt instruments that do not meet the conditions in FRS 102 paragraph 11.9 are subsequently measured at fair value through profit or loss. Debt instruments may be designated as being measured at fair value through profit or loss to eliminate or reduce an accounting mismatch or if the instruments are measured and their performance evaluated on a fair value basis in accordance with a documented risk management or investment strategy.

Derecognition of financial liabilities

Financial liabilities are derecognised when the company’s contractual obligations expire or are discharged or cancelled.

1.5
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.6
Derivatives

Derivatives are initially recognised at fair value at the date a derivative contract is entered into and are subsequently remeasured to fair value at each reporting end date. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship.

 

A derivative with a positive fair value is recognised as a financial asset, whereas a derivative with a negative fair value is recognised as a financial liability.

1.7
Foreign exchange

Transactions in currencies other than pounds sterling are recorded at the rates of exchange prevailing at the dates of the transactions. At each reporting end date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the reporting end date. Gains and losses arising on translation in the period are included in profit or loss.

Nucleus Commercial Holdings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 16
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Operating loss
2025
2024
Operating loss for the year is stated after charging:
£
£
Fees payable to the company's auditor for the audit of the company's financial statements
23,699
25,987
4
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
0
0
5
Taxation

The actual charge for the year can be reconciled to the expected credit for the year based on the profit or loss and the standard rate of tax as follows:

2025
2024
£
£
Loss before taxation
(63,658)
(1,334,202)
Expected tax charge based on the standard rate of corporation tax in the UK of 0% (2024: 0%)
-
0
-
0
Taxation charge in the financial statements
-
-
Nucleus Commercial Holdings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 17
6
Fixed asset investments
2025
2024
Notes
£
£
Investments in subsidiaries
7
4,632,101
4,633,401
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 April 2024 & 31 March 2025
4,633,401
Impairment
At 1 April 2024
-
Impairment losses
1,300
At 31 March 2025
1,300
Carrying amount
At 31 March 2025
4,632,101
At 31 March 2024
4,633,401
7
Subsidiaries

These financial statements are separate company financial statements for XXX.

Details of the company's subsidiaries at 31 March 2025 are as follows:

Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Nucleus Commercial Finance Limited
UK
Ordinary Shares
100.00
Nucleus Commercial Finance1 Limited
UK
Ordinary Shares
100.00
Nucleus Property Finance Limited
UK
Ordinary Shares
100.00
Nucleus Property Finance1 Limited
UK
Ordinary Shares
100.00
Nucleus Cash Flow Finance Limited
UK
Ordinary Shares
100.00
Nucleus Business Cash Advance Limited
UK
Ordinary Shares
100.00
Nucleus Services Limited
UK
Ordinary Shares
100.00
Nucleus Asset Finance Limited
UK
Ordinary Shares
100.00
Nucleus Commercial Holdings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 18
8
Debtors
2025
2024
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
2,624,873
1,501,499
Other debtors
-
0
102
2,624,873
1,501,601
9
Creditors: amounts falling due within one year
2025
2024
£
£
Amounts owed to group undertakings
200
200
Accruals and deferred income
30,443
15,000
30,643
15,200
10
Share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
100
100
100
100
11
Cash absorbed by operations
2025
2024
£
£
Loss for the year after tax
(63,658)
(1,334,202)
Movements in working capital:
(Increase)/decrease in debtors
(1,123,272)
1,106,598
Increase in creditors
15,443
4,283
Cash absorbed by operations
(1,171,487)
(223,321)
Difference
300
1,299,911
Per cash flow statement page
(1,171,187)
1,076,590
Nucleus Commercial Holdings Limited
Notes to the Financial Statements (Continued)
For the year ended 31 March 2025
Page 19
12
Analysis of changes in net funds
1 April 2024
Cash flows
31 March 2025
£
£
£
Cash at bank and in hand
1,178,712
(1,170,187)
8,525
2025-03-312024-04-01falsefalsefalseCCH SoftwareCCH Accounts Production 2025.300C ShahM GoldmanD WinwardG TitleyS Willmett096467282024-04-012025-03-3109646728bus:Director22024-04-012025-03-3109646728bus:Director32024-04-012025-03-3109646728bus:Director42024-04-012025-03-3109646728bus:Director52024-04-012025-03-3109646728bus:Director12024-04-012025-03-3109646728bus:RegisteredOffice2024-04-012025-03-31096467282025-03-31096467282023-04-012024-03-3109646728core:RetainedEarningsAccumulatedLosses2023-04-012024-03-3109646728core:RetainedEarningsAccumulatedLosses2024-04-012025-03-31096467282024-03-3109646728core:CurrentFinancialInstrumentscore:WithinOneYear2025-03-3109646728core:CurrentFinancialInstrumentscore:WithinOneYear2024-03-3109646728core:CurrentFinancialInstruments2025-03-3109646728core:CurrentFinancialInstruments2024-03-3109646728core:ShareCapital2025-03-3109646728core:ShareCapital2024-03-3109646728core:SharePremium2025-03-3109646728core:SharePremium2024-03-3109646728core:RetainedEarningsAccumulatedLosses2025-03-3109646728core:RetainedEarningsAccumulatedLosses2024-03-3109646728core:ShareCapital2023-03-3109646728core:SharePremium2023-03-3109646728core:RetainedEarningsAccumulatedLosses2023-03-3109646728core:ShareCapitalOrdinaryShareClass12025-03-3109646728core:ShareCapitalOrdinaryShareClass12024-03-31096467282024-03-31096467282023-03-3109646728core:UKTax2024-04-012025-03-3109646728core:UKTax2023-04-012024-03-3109646728core:Non-currentFinancialInstruments2025-03-3109646728core:Non-currentFinancialInstruments2024-03-3109646728core:Subsidiary12024-04-012025-03-3109646728core:Subsidiary22024-04-012025-03-3109646728core:Subsidiary32024-04-012025-03-3109646728core:Subsidiary42024-04-012025-03-3109646728core:Subsidiary52024-04-012025-03-3109646728core:Subsidiary62024-04-012025-03-3109646728core:Subsidiary72024-04-012025-03-3109646728core:Subsidiary82024-04-012025-03-3109646728core:Subsidiary112024-04-012025-03-3109646728core:Subsidiary222024-04-012025-03-3109646728core:Subsidiary332024-04-012025-03-3109646728core:Subsidiary442024-04-012025-03-3109646728core:Subsidiary552024-04-012025-03-3109646728core:Subsidiary662024-04-012025-03-3109646728core:Subsidiary772024-04-012025-03-3109646728core:Subsidiary882024-04-012025-03-3109646728bus:OrdinaryShareClass12024-04-012025-03-3109646728bus:OrdinaryShareClass12025-03-3109646728bus:OrdinaryShareClass12024-03-3109646728bus:PrivateLimitedCompanyLtd2024-04-012025-03-3109646728bus:FRS1022024-04-012025-03-3109646728bus:Audited2024-04-012025-03-3109646728bus:FullAccounts2024-04-012025-03-31xbrli:purexbrli:sharesiso4217:GBP